PBMs the winners as White House scraps rebate proposal

12 July 2019
white_house_big

Shares in major pharmaceutical companies fell on Thursday, after the US government said it would abandon a proposal to require health insurers to pass significant rebates on to Medicare patients.

Drugmakers  are estimated to pay out in excess of $100 billion per year in rebates, with Pharmacy Benefit Managers (PBM) the primary beneficiaries.

Companies which negotiate discounts with drugmakers will be allowed to continue benefiting from those rebates.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical